Cargando…

Light Chain Stabilization: A Therapeutic Approach to Ameliorate AL Amyloidosis

Non-native immunoglobulin light chain conformations, including aggregates, appear to cause light chain amyloidosis pathology. Despite significant progress in pharmacological eradication of the neoplastic plasma cells that secrete these light chains, in many patients impaired organ function remains....

Descripción completa

Detalles Bibliográficos
Autores principales:	Morgan, Gareth J., Buxbaum, Joel N., Kelly, Jeffery W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9218996/ https://www.ncbi.nlm.nih.gov/pubmed/35757512 http://dx.doi.org/10.3390/hemato2040042

Ejemplares similares

Light Chain (AL) Amyloidosis: The Journey to Diagnosis
por: McCausland, Kristen L., et al.
Publicado: (2017)

Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
por: Palladini, Giovanni, et al.
Publicado: (2021)

Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis
por: Zhang, Kathleen W., et al.
Publicado: (2019)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Differences in Immunoglobulin Light Chain Species Found in Urinary Exosomes in Light Chain Amyloidosis (AL)
por: Ramirez-Alvarado, Marina, et al.
Publicado: (2012)

Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2018)

Racial disparities in patients diagnosed with light chain (AL) amyloidosis
por: D’Souza, Anita, et al.
Publicado: (2021)

Light Chain (AL) Cardiac Amyloidosis: A Diagnostic Dilemma
por: Abdelazeem, Basel, et al.
Publicado: (2021)

Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2013)

Identification of Candidate Genes and Therapeutic Agents for Light Chain Amyloidosis Based on Bioinformatics Approach
por: Bai, Wenxiang, et al.
Publicado: (2019)

Mutations in Specific Structural Regions of Immunoglobulin Light Chains Are Associated with Free Light Chain Levels in Patients with AL Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2009)

Early relapse is an adverse prognostic marker in systemic immunoglobulin light chain (AL) Amyloidosis
por: Ravichandran, Sriram, et al.
Publicado: (2022)

(99m)Tc-DPD scintigraphy in immunoglobulin light chain (AL) cardiac amyloidosis
por: Quarta, Candida Cristina, et al.
Publicado: (2021)

Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach
por: Hwa, Yi L., et al.
Publicado: (2019)

Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
por: Wechalekar, A D, et al.
Publicado: (2017)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

Supportive Care and Symptom Management for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
por: Jensen, Christopher E., et al.
Publicado: (2022)

Novel Therapies in Light Chain Amyloidosis
por: Milani, Paolo, et al.
Publicado: (2017)

DUAL expectations in light chain amyloidosis
por: Schönland, Stefan, et al.
Publicado: (2020)

Splenic rupture secondary to amyloid light-chain (AL) amyloidosis associated with multiple myeloma
por: Buzalewski, Jarrod, et al.
Publicado: (2019)

Lingual liability: macroglossia and dyspnoea as the harbinger of systemic AL (light-chain) cardiac amyloidosis
por: Williams, Michael Uncle, et al.
Publicado: (2018)

Understanding Mesangial Pathobiology in AL-Amyloidosis and Monoclonal Ig Light Chain Deposition Disease
por: Herrera, Guillermo A., et al.
Publicado: (2020)

Treatment Options For Relapsed/refractory Systemic Light-Chain (AL) Amyloidosis: Current Perspectives
por: Sarosiek, Shayna, et al.
Publicado: (2019)

The Role of Light Kappa and Lambda Chains in Heart Function Assessment in Patients with AL Amyloidosis
por: Czyżewska, Emilia, et al.
Publicado: (2021)

Autopsy findings in a patient with primary systemic AL (kappa light chain) amyloidosis
por: Ledesma, Felipe Lourenço, et al.
Publicado: (2021)

Dissecting the Molecular Features of Systemic Light Chain (AL) Amyloidosis: Contributions from Proteomics
por: Rognoni, Paola, et al.
Publicado: (2021)

Jejunal Wall Thickening and Ulceration in a Patient With Amyloid Light-chain (AL) Amyloidosis
por: Drory, Samuel Bernard, et al.
Publicado: (2020)

Global epidemiology of amyloid light-chain amyloidosis
por: Kumar, Nishant, et al.
Publicado: (2022)

Light chain amyloidosis presenting as retiform purpura
por: Soliman, Yssra S., et al.
Publicado: (2021)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

Localized Lymph Node Light Chain Amyloidosis
por: Dhakal, Binod, et al.
Publicado: (2015)

Importance of FISH genetics in light chain amyloidosis
por: Gertz, Morie A., et al.
Publicado: (2017)

Kappa light-chain amyloidosis of gastrointestinal tract
por: Hashimoto, Rintaro, et al.
Publicado: (2019)

Multiorgan involvement by amyloid light chain amyloidosis
por: Li, Guoliang, et al.
Publicado: (2019)

Localized Lymph Node Light Chain Amyloidosis
por: Yamamoto, Akira, et al.
Publicado: (2020)

Light chain cardiac amyloidosis in a nonagenarian
por: Takahashi, Koji, et al.
Publicado: (2022)

Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication
por: Baker, Kelty R.
Publicado: (2022)

COVID-19 and Light Chain Amyloidosis: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022)

T1 mapping and survival in systemic light-chain amyloidosis
por: Banypersad, Sanjay M., et al.
Publicado: (2015)

Neuropathy and efficacy of once weekly subcutaneous bortezomib in multiple myeloma and light chain (AL) amyloidosis
por: Sidana, Surbhi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_91al5okvv24dri632jha6q4cfs